IKT vs TFC · $215.2M cap vs rev $11.82B
Inhibikase Therapeutics Inc (IKT) versus TFC (TFC) — a side-by-side from cached financials, not a winner call.
Inhibikase Therapeutics Inc (IKT) is a biotechnology company listed on US.
TFC (TFC) common stock.
Latest reported IKT revenue for 2026-06-30 was $0. Net income was -$36.0M. IKT currently screens at market cap $215.2M.
Latest reported TFC revenue for 2026-06-30 was $11.82B. Net income was $3.03B. TFC currently screens at market cap $0.
IKT currently screens at market cap $215.2M. TFC currently screens at market cap $0.
Not investment advice. Open the IKT and TFC stock pages for the full models.
Not investment advice.